Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 8, 2015, 59 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.90 to $2,613,411,881.91.

Highlighted Stocks Traded by Insiders:

KCG Holdings (KCG) - FREE Research Report

Daniel V. Tierney 2011 Trust, who is 10% Owner at KCG Holdings, sold 26,067 shares at $12.36 on April 8, 2015. Following this transaction, the 10% Owner owned 8.6 million shares meaning that the stake was reduced by 0.3% with the 26,067-share transaction.

The shares most recently traded at $12.34, down $0.02, or 0.14% since the insider transaction. Historical insider transactions for KCG Holdings go as follows:

  • 4-Week # shares sold: 352,220
  • 12-Week # shares sold: 620,555
  • 24-Week # shares sold: 620,555

The average volume for KCG Holdings has been 303,400 shares per day over the past 30 days. KCG Holdings has a market cap of $1.3 billion and is part of the financial sector and financial services industry. Shares are up 6.18% year-to-date as of the close of trading on Wednesday.

KCG Holdings, Inc., an independent securities firm, provides various services designed to address trading needs across asset classes, product types, and time zones. The company operates through three segments: Market Making, Global Execution Services, and Corporate and Other. The company has a P/E ratio of 22.7. Currently, there are 2 analysts who rate KCG Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KCG - FREE

TheStreet Quant Ratings rates KCG Holdings as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full KCG Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alon USA Energy (ALJ) - FREE Research Report

Hart Claire A, who is Senior Vice President at Alon USA Energy, sold 20,000 shares at $16.45 on April 8, 2015. Following this transaction, the Senior Vice President owned 525,725 shares meaning that the stake was reduced by 3.66% with the 20,000-share transaction.

The shares most recently traded at $16.00, down $0.45, or 2.8% since the insider transaction. Historical insider transactions for Alon USA Energy go as follows:

  • 4-Week # shares sold: 18,000
  • 12-Week # shares bought: 4,000
  • 12-Week # shares sold: 3.9 million
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 4.3 million

The average volume for Alon USA Energy has been 1.1 million shares per day over the past 30 days. Alon USA Energy has a market cap of $1.1 billion and is part of the basic materials sector and energy industry. Shares are up 27.39% year-to-date as of the close of trading on Wednesday.

Alon USA Energy, Inc. engages in refining and marketing petroleum products, primarily in the South Central, Southwestern, and Western regions of the United States. It operates in three segments: Refining and Marketing, Asphalt, and Retail. The stock currently has a dividend yield of 2.45%. The company has a P/E ratio of 29.6. Currently, there is 1 analyst who rates Alon USA Energy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALJ - FREE

TheStreet Quant Ratings rates Alon USA Energy as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. Get the full Alon USA Energy Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Bentsur Ron, who is Chief Executive Officer at Keryx Biopharmaceuticals, sold 1,592 shares at $11.68 on April 8, 2015. Following this transaction, the Chief Executive Officer owned 777,209 shares meaning that the stake was reduced by 0.2% with the 1,592-share transaction.

Oliviero James F III, who is Chief Financial Officer at Keryx Biopharmaceuticals, sold 1,878 shares at $11.68 on April 8, 2015. Following this transaction, the Chief Financial Officer owned 169,738 shares meaning that the stake was reduced by 1.09% with the 1,878-share transaction.

The shares most recently traded at $12.34, up $0.66, or 5.35% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares sold: 6,759
  • 12-Week # shares sold: 6,759
  • 24-Week # shares sold: 545,736

The average volume for Keryx Biopharmaceuticals has been 1.8 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are down 12.51% year-to-date as of the close of trading on Wednesday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 10 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Keryx Biopharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null